Elevated blood-sugar levels in pregnancy tied to baby's heart-defect risk

Congenital heart defects are correlated with moderate elevation of the mother’s blood sugar during pregnancy, even if she’s not diabetic, according to a new study.

A Stanford study shows that pregnant women with elevated blood-sugar levels are at greater risk for having babies with congenital heart defects.
Shutterstock

Pregnant women with elevated blood-sugar levels are more likely to have babies with congenital heart defects, even if their blood sugar is below the cutoff for diabetes, according to a new study from the Stanford University School of Medicine and Stanford Children’s Health.

The study, published online Oct. 12 in JAMA Pediatrics, extends the scope of prior findings on the connection between maternal diabetes and fetal heart defects. It is the first to show the link in women without a diabetes diagnosis.

“Diabetes is the tail end of a spectrum of metabolic abnormalities,” said James Priest, MD, the study’s lead author and a postdoctoral scholar in pediatric cardiology. “We already knew that women with diabetes were at significantly increased risk for having children with congenital heart disease. What we now know, thanks to this new research, is that women who have elevated glucose values during pregnancy that don’t meet our diagnostic criteria for diabetes also face an increased risk.” Priest treats patients with congenital heart defects at the Children’s Heart Center at Lucile Packard Children’s Hospital Stanford.

Pregnancy normally involves metabolic changes that make blood sugar — glucose — more available to the fetus than to the mother, an important adaptation for ensuring that the fetus gets enough nourishment. However, in some women, especially those who are obese or who have a family history of diabetes, these changes progress too far, to the point that the mother develops gestational diabetes. Although the risks of gestational diabetes have been well-studied, less attention has been paid to smaller metabolic changes in pregnancy.

Two serious heart defects

In the new study, the researchers examined blood samples taken from 277 California women during the second trimester of pregnancy. The control group comprised 180 women carrying infants without congenital heart disease. The others had infants affected by one of two serious heart defects. Fifty-five infants had tetralogy of Fallot, which is characterized by structural problems in the heart and in the blood vessels that connect the heart to the lungs; it is the most common of the heart defects that cause blue baby syndrome, in which a baby is getting too little oxygen. The remaining 42 infants had dextrotransposition of the great arteries, in which the positions of the two main arteries leading from the heart are swapped, preventing oxygenated blood from the lungs from circulating to the body.

James Priest

The blood samples were collected at different times of the day, and the women were not asked to fast before sample collection. The researchers measured the women’s levels of glucose, the main form of blood sugar, and insulin, a hormone that controls blood sugar.

The researchers found that average blood glucose levels were higher in women carrying fetuses with tetralogy of Fallot than in women in the control group, but were not elevated in women whose fetuses had dextrotransposition of the great arteries. However, women whose fetuses had dextrotransposition of the great arteries had significantly elevated insulin levels.

The scientists used a mathematical model that accounted for both glucose and insulin levels, and was adjusted for the woman’s age and ethnicity and whether she had diabetes. In the model, higher glucose levels were correlated with the odds of having a baby with tetralogy of Fallot, but not with dextrotransposition of the great arteries. In the model, however, the relationship with insulin levels was not significant for either birth defect.

Fuel for cells

Glucose is a fundamental fuel for cells, Priest noted, so it is unlikely that it is high glucose itself that damages the fetal heart. “It has to act via some mechanism,” he said, adding that the cell’s machinery for handling glucose overlaps with important developmental signaling mechanisms, such as the insulin-like growth factor receptors.

“I’m excited by this research because it opens up a lot of questions about how physiologic processes in the mother may be related to congenital heart disease,” Priest said. “Most of the time we don’t have any idea what causes a baby’s heart defect. I aim to change that.”

Most of the time we don’t have any idea what causes a baby’s heart defect. I aim to change that.

The work is an example of Stanford Medicine’s focus on precision health by generating care that is proactive, predictive and personalized.

The study’s senior author, Gary Shaw, DrPH, professor of pediatrics in neonatal and developmental medicine, added, “There are several other kinds of structural birth defects, in addition to heart defects, that have been linked with overt diabetes. This new work will motivate us to ask if underlying associations with moderately increased glucose levels may be similarly implicated in risks of some of these other birth defects.”  

Other Stanford-affiliated authors of the study are Wei Yang, data analyst in pediatrics; Gerald Reaven, MD, professor emeritus of medicine; and Joshua Knowles, MD, PhD, assistant professor of cardiovascular medicine. Reaven, Knowles and Shaw are members of the Stanford Child Health Research Institute.

The research was supported by the National Institutes of Health (grants HL085859, P60DK20579 and K12HD000850), the Stanford Cardiovascular Institute and the American Heart Association. Biospecimens and data used in the study were obtained from the California Biobank Program.

Stanford’s Department of Pediatrics also supported the work. 


Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.

Leading in Precision Health

Stanford Medicine is leading the biomedical revolution in precision health, defining and developing the next generation of care that is proactive, predictive and precise. 

A Legacy of Innovation

Stanford Medicine's unrivaled atmosphere of breakthrough thinking and interdisciplinary collaboration has fueled a long history of achievements.